C. difficile

With cuts to the Department of Health and Human Services incoming, efforts to research, surveil, and prevent infections of Clostridioides difficile could be derailed.

Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses a study she conducted that highlights how social determinants of health exacerbate severity and increase rates of mortality from Clostridioides difficile infections in vulnerable communities.

New technology and innovation may help turn the corner on antibiotic resistance.

RBL is the first FDA-approved microbiota-based live biotherapeutic product for adults.

Educating the public about the dangers of self-medication and the importance of finishing prescribed antibiotic courses plays a crucial role

Pharmacists play a key role in the use of live biotherapeutic products, including fecal microbiota, live-jslm for prevention of recurrent Clostridioides difficile (C difficile) infection.

The BLING III trial investigated continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis, finding no significant difference in 90-day mortality but suggesting potential benefits in clinical cure rates.

Vincent Young, MD, PhD, shares takeaways from Peggy Lillis Foundation's 2024 National C diff Advocacy Summit.

The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Scientists hypothesize that fecal microbiota transplant restores the recipient’s gut microbiota to an environment that mimics the healthy donor’s microbiota